Competitive Clinical Research Grant
Eli Lilly's grant funds independent clinical research on lebrikizumab and mirkizumab in dermatology and IBD, with investigators leading study design and execution.
Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Full application due — Efficacy of Lebrikizumab in fibrosing skin conditions | February 15, 2026: Full application due — Lebrikizumab impact on post-inflammatory dyspigmentation in atopic dermatitis | June 15, 2026: Full application due — Real-world effectiveness of mirkizumab in IBD (Canada)
Funding Amounts: Funding and/or Lilly study drug support; specific amounts not published—varies by project scope and RFP.
Summary: Supports independent, externally initiated clinical research in Lilly’s areas of interest, with funding or study drug provided through competitive RFPs.
Key Information: Grantee is responsible for study design, conduct, and regulatory sponsorship.
Description
The Competitive Clinical Research Grant from Eli Lilly and Company is designed to support investigator-initiated clinical research that aligns with Lilly’s scientific areas of interest. Funding is provided through public Requests for Proposals (RFPs) that specify targeted research questions or therapeutic areas, such as dermatology and gastroenterology. Selected projects may receive financial support, provision of Lilly study drug, or both, with the grantee retaining full responsibility for study design, conduct, and regulatory sponsorship. Proposals are reviewed by global committees of Lilly medical and scientific staff, and may also involve external experts for final selection.
